You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR JANTOVEN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for JANTOVEN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02574754 ↗ Assessment of 2012 Bioequivalence Standards for Warfarin Completed University of California, San Francisco Phase 1 2016-05-01 The purpose of this study is to assess the 2012 bioequivalence statistical criteria for warfarin, a narrow therapeutic index drug, set forth in the draft guidance issued by the Food and Drug Administration (FDA).
NCT02942407 ↗ Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation Completed Bristol-Myers Squibb Phase 4 2016-12-01 This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) .
NCT02942407 ↗ Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation Completed Christopher Granger Phase 4 2016-12-01 This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) .
NCT02942407 ↗ Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation Completed Christopher Granger, MD Phase 4 2016-12-01 This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) .
NCT02943785 ↗ Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF) Completed Chiltern International Inc. Phase 3 2017-03-21 When the upper chambers of a person's heart receive irregular electrical signals it causes abnormal rhythm in the heart beat. This is called atrial fibrillation. Atrial fibrillation increases the chance of having a heart attack or stroke. Some patients also get new heart valves using a catheter. Often doctors give patients a medicine called a vitamin K antagonist (VKA), because it is considered the standard care. This study will see how edoxaban compares to VKA in patients who got a new heart valve by using a catheter. The study will compare the two drugs for up to three years after heart valve replacement, looking at the drug's overall side effects (called adverse events) and major bleeding.
NCT02943785 ↗ Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF) Completed Daiichi Sankyo Inc. Phase 3 2017-03-21 When the upper chambers of a person's heart receive irregular electrical signals it causes abnormal rhythm in the heart beat. This is called atrial fibrillation. Atrial fibrillation increases the chance of having a heart attack or stroke. Some patients also get new heart valves using a catheter. Often doctors give patients a medicine called a vitamin K antagonist (VKA), because it is considered the standard care. This study will see how edoxaban compares to VKA in patients who got a new heart valve by using a catheter. The study will compare the two drugs for up to three years after heart valve replacement, looking at the drug's overall side effects (called adverse events) and major bleeding.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for JANTOVEN

Condition Name

Condition Name for JANTOVEN
Intervention Trials
Atrial Fibrillation 2
Atrial Fibrillation and Flutter 1
Drug Interaction Potential 1
End Stage Renal Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for JANTOVEN
Intervention Trials
Atrial Fibrillation 3
Kidney Failure, Chronic 2
Atrial Flutter 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for JANTOVEN

Trials by Country

Trials by Country for JANTOVEN
Location Trials
United States 71
Japan 12
Korea, Republic of 6
Spain 5
Canada 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for JANTOVEN
Location Trials
California 4
New York 3
Michigan 3
Massachusetts 3
Washington 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for JANTOVEN

Clinical Trial Phase

Clinical Trial Phase for JANTOVEN
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for JANTOVEN
Clinical Trial Phase Trials
Completed 4
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for JANTOVEN

Sponsor Name

Sponsor Name for JANTOVEN
Sponsor Trials
Daiichi Sankyo, Inc. 2
Christopher Granger, MD 1
Chiltern International Inc. 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for JANTOVEN
Sponsor Trials
Other 5
Industry 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.